MacroGenics | MGNX - Operating Profit


MacroGenics reported $-33.44M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Amgen USD 4.61B 777M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Daiichi Sankyo JPY 85.1B 4.44B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Genmab DKK 260M 199M Dec/2025
Geron USD -236K 10.55M Mar/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
J&J USD 7.48B 860M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -33.44M 21.34M Mar/2026
Merck USD 840M 2.72B Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Xencor USD -36.6M 41.26M Jun/2026